Clinical trials: Cancer Support
Metastatic Colorectal Cancer, Advanced Colorectal Cancer
Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer
RBS2418 is a specific immune modulator that works through the inhibition of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and is designed to lead to anti-tumor immunity by protecting endogenous 2'-3'-cyclic guanosine…
- Trial name
- VISTA-1 (NCT06824064)
- Testing
- RBS2418
- Where
- 5 sites in United States, Puerto Rico and 1 more
- Volunteers
- 150 people
- Sponsor
- Riboscience, LLC.
Insomnia, Breast Cancer
PERSONAL - Sleep In Breast Cancer
Sleep is essential for human function, immunity, and well-being. In the general population, sleep disturbance and insomnia cause significant health problems and impact on the quality of life of many individuals.
- Trial name
- NCT05093426
- Testing
- Stage 2 Digital sleep diary app
- Where
- United Kingdom
- Volunteers
- 226 people
- Sponsor
- Closed Loop Medicine
Gastric Cancer, Gastric Adenocarcinoma
A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer
The purpose of this study is to evaluate the efficacy and safety of rivoceranib plus best supportive care (BSC) compared to placebo plus BSC in participants with advanced or metastatic gastric cancer (GC).
- Trial name
- ANGEL (NCT03042611)
- Testing
- Rivoceranib
- Where
- 95 sites in United States, France and 10 more
- Volunteers
- 460 people
- Sponsor
- Elevar Therapeutics
Neutropenic Complications, Breast Neoplasms
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Neulasta®
The study will assess the efficacy of LA-EP2006 compared to Neulasta® with respect to the mean duration of severe neutropenia during treatment with myelosuppressive chemotherapy in breast cancer patients.
- Conditions
- Neutropenic Complications, Breast Neoplasms, Chemotherapy-induced Neutropenia, Chemotherapeutic Toxicity
- Trial name
- PROTECT-1 (NCT01735175)
- Testing
- LA-EP2006, Neulasta®
- Where
- 41 sites in Brazil, India and 4 more
- Volunteers
- 316 people
- Sponsor
- Sandoz
Breast Cancer
Evaluating the Adequacy of Giro-Couch to Support Prone Breast Boost Irradiation Using IMRT Technique With IGRT.
The purpose of this study is to evaluate the Giro-couch, an innovative patient support device for the application of prone RT for treatment of breast cancer.
- Trial name
- IN902 (NCT01016574)
- Testing
- Support Device for Prone radiation therapy (Giro-Couch)
- Where
- Israel
- Volunteers
- 15 people
- Sponsor
- Azimuth Therapy Ltd.
Neoplasms, Thrombocytopenia
Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia
Intensive chemotherapy is associated with significant thrombocytopenia, often requiring platelet transfusion to maintain platelet counts. This investigational drug has demonstrated the ability to increase platelet counts.
- Conditions
- Neoplasms, Thrombocytopenia, Multiple Myeloma, Lymphoma, Malignant
- Trial name
- NCT00037791
- Testing
- (PN-152,243)/PN-196,444
- Where
- 9 sites in United States, Argentina and 1 more
- Volunteers
- 180 people
- Sponsor
- Pfizer
NSCLC
Iressa v BSC (Best Supportive Care) in First Line NSCLC
The purpose of the study is to determine if the addition of Iressa to Best Supportive Care treatment will increase the progression free survival of chemo-naïve, poor performance status patients, with stage IIIB or IV NSCLC.
- Trial name
- INSTEP (NCT00259064)
- Testing
- Gefitinib
- Where
- 36 sites in Australia, Canada and 3 more
- Volunteers
- 216 people
- Sponsor
- AstraZeneca
Pancreatic Neuroendocrine Tumors (pNET)
BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy.
This is a Phase II study in 2 stages, evaluating BEZ235 plus best supportive care (BSC) versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumors (pNET) after failure of mTOR inhibitor therapy.
- Trial name
- NCT01658436
- Testing
- BEZ235 (Stage 1)
- Where
- 17 sites in United States, Austria and 7 more
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Locally Advanced (Unresectable) or Metastatic Adenocarcinoma of the Gastric and Gastro-esophageal Junction
An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy
The purpose of the study is to compare the efficacy of Ipilimumab and standard of care as sequential or maintenance treatment immediately after first-line chemotherapy in the treatment of unresectable or metastatic gastric and…
- Trial name
- NCT01585987
- Testing
- Ipilimumab, Best Supportive care (BSC)
- Where
- 36 sites in United States, France and 10 more
- Volunteers
- 143 people
- Sponsor
- Bristol-Myers Squibb
Metastatic Colorectal Cancer, Colorectal Cancer
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
The purpose of this study is to evaluate whether therapy with MORAb-004 is effective and safe in the treatment of metastatic, colorectal cancer.
- Trial name
- NCT01507545
- Testing
- MORAb-004, Best supportive care
- Where
- 67 sites in United States
- Volunteers
- 154 people
- Sponsor
- Morphotek
Liver Cirrhosis, Refractory Ascites
ALFApump System Post Marketing Surveillance Registry
This is a post market surveillance registry to monitor the safety and performance of the ALFApump system.
- Conditions
- Liver Cirrhosis, Refractory Ascites, Malignant Ascites
- Trial name
- 2011-AAR-004 (NCT01532427)
- Where
- 13 sites in Germany, Spain and 2 more
- Volunteers
- 100 people
- Sponsor
- Sequana Medical N.V.
Colon Cancer
Dose-Escalation Study in Advanced Colon Cancer Patients
This study is exploring different administration schedules (short versus prolonged infusion) to optimize the safety and efficacy profile of EPO906A (patupilone) in patients with pretreated advanced colon cancer.
- Trial name
- NCT00969046
- Testing
- EPO906 (patupilone)
- Where
- 6 sites in Czechia, France and 2 more
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
Non-Small-Cell Lung Carcinoma
ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures
This study is being carried out to assess if adding ZD6474 to best supportive care (BSC) is more effective than best supportive care alone, for the treatment of patients with non-small cell lung cancer, whose disease has recurred…
- Trial name
- NCT00404924
- Testing
- ZD6474 (vandetanib), Best Supportive Care
- Where
- 102 sites in United States, Argentina and 20 more
- Volunteers
- 1,140 people
- Sponsor
- Genzyme, a Sanofi Company
Lung Neoplasms
Tax First-line Chemotherapy With Different Doses and Then Maintenance Therapy
The Primary Objective is to evaluate the progression-free survival (PFS). The secondary objectives are: To compare the disease control rates of different doses of Docetaxel+Cisplatin as first-line treatment according to Response…
- Trial name
- TFINE (NCT01038661)
- Testing
- Docetaxel, Cisplatin, Best supportive care (BSC)
- Where
- China
- Volunteers
- 375 people
- Sponsor
- Sanofi
Gastric Cancer, Adenocarcinoma
Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma
The purpose of this study is to gather information about the use of an investigational drug called Ramucirumab in adenocarcinomas of the stomach or gastroesophageal junction.
- Trial name
- NCT00917384
- Testing
- ramucirumab, Best Supportive Care (BSC)
- Where
- 161 sites in United States, Argentina and 28 more
- Volunteers
- 355 people
- Sponsor
- Eli Lilly and Company
Hepatocellular Carcinoma
Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy
This is a study of ADI-PEG 20 (pegylated arginine deiminase), an arginine degrading enzyme versus placebo in patients with hepatocellular carcinoma who have failed prior systemic treatment (chemotherapy).
- Trial name
- ADI-PEG 20 (NCT01287585)
- Testing
- ADI-PEG 20 (arginine deiminase formulated with polyethylene glycol), Best Supportive Care
- Where
- 73 sites in United States, China and 4 more
- Volunteers
- 636 people
- Sponsor
- Polaris Group
Urothelial Cancer
A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100)
The main purpose of this study is to compare maintenance treatment with avelumab plus best supportive care (BSC) with BSC alone, to determine if avelumab has an effect on survival in patients with locally advanced or metastatic…
- Trial name
- NCT02603432
- Testing
- Avelumab, Best Supportive Care, Following the planned interim analysis for this study: Avelumab
- Where
- 382 sites in United States, Argentina and 27 more
- Volunteers
- 700 people
- Sponsor
- Pfizer
Prostate Cancer, Prostate Cancer Screening Decision
Clinical Utility of ClarityDX Prostate
ClarityDX Prostate builds upon the utility of total and free PSA as well as simple clinical features in a decision support model to determine a patient's risk of having clinically significant prostate cancer.
- Conditions
- Prostate Cancer, Prostate Cancer Screening Decision, Prostate Cancer Screening
- Trial name
- NCT06678828
- Testing
- ClarityDX Prostate, ClarityDX Prostate, blinded
- Where
- 5 sites in Canada
- Volunteers
- 1,450 people
- Sponsor
- Nanostics
Carcinoma, Non-small-cell Lung
Randomized Study Of CP-675,206 or Best Supportive Care Immediately After Platinum-Based Therapy For Non-Small Cell Lung Cancer (NSCLC)
The purpose of this trial is to study how long patients can remain progression free when they receive CP-675,206, compared to how long patients can remain progression free when they receive best supportive care.
- Trial name
- NCT00312975
- Testing
- CP-675,206, best supportive care
- Where
- 26 sites in United States, Canada and 3 more
- Volunteers
- 90 people
- Sponsor
- AstraZeneca
Radiation Dermatitis, Breast Cancer
Effect of a Mushroom Extract-Containing Topical Cosmetic Formulation During Breast Radiotherapy
This study evaluated a mushroom extract-containing topical cosmetic formulation for skin care in women receiving radiotherapy to the breast after breast-conserving surgery.
- Trial name
- NCT07755553
- Testing
- Mushroom extract-containing topical cosmetic formulation, Usual moisturizing cosmetic care
- Where
- Spain
- Volunteers
- 50 people
- Sponsor
- Hifas da Terra S.L.